Potential treatment option for patients who are ineligible for cisplatin
Immune toxicity remains a diagnosis of exclusion, and multidisciplinary collaboration remains the cornerstone for early diagnosis and treatment.
Community-based data help predict patients’ response to immune checkpoint inhibitors
Study finds high levels of a CD8 T-cell subpopulation to be predictive of ICI resistance
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Common cancer therapy increases serious risks in murine models
Durvalumab monotherapy appears safe and well-tolerated
Proposing a classification system for irAEs
